Incidental Cancer in Gallbladder Surgical Specimens Focus on Elderly Patients

Pathology Clinical Trial

Official title:

Incidental Cancer in Gallbladder Surgical Specimens Focus on Elderly Patients, Retrospective Analysis of 2389 Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04352478
• Other study ID #: 13042020
• Status: Completed
• Start date: January 20, 2020
• Est. completion date: April 13, 2020

Study information

• Verified date: April 2020
• Source: Dr. Ersin Arslan Education and Training Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Causes such as long-term stones and polyp are thought to play a role in the etiology of gallbladder cancer. The routine histopathological examination provides the detection of incidental gallbladder cancers. It should be remembered that acute or chronic cholecystitis accompanied by the thicked wall and a prolonged history of gallstones may be the cause of malignancy, especially in elderly patients.

Description:

The investigators aimed to incidental gallbladder cancer and compare other pathology results with elderly patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2389
• Est. completion date: April 13, 2020
• Est. primary completion date: April 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• acute cholecystectomy

• elective cholecystectomy

Exclusion Criteria:

• lack of data

• incidental cholecystectomy,

• cholecystectomy secondary to trauma

• cholecystectomy secondary to malignancy

Related Conditions & MeSH terms

• Pathology

Intervention

Diagnostic Test:
• Histopathological result
Incidental gallbladder cancer and other pathology

Locations

Country	Name	City	State
Turkey	Dr. Ersin Arslan Training and Resource Hospital	Gaziantep

Sponsors (1)

Lead Sponsor	Collaborator
Dr. Ersin Arslan Education and Training Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Incidental Cancer	Number of Participants with adenocarcinom	2 or 3 week